id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0326-0008,FDA,FDA-2003-E-0326,"Certificate Extending Patent Term from U.S. Patent and Trademark Office to Fitzpatrick, Celia, Harper & Scinto",Rule,Certificate Extending Patent Term,2007-03-15T04:00:00Z,2007,3,,,2025-10-27T23:05:57Z,,0,0,0900006480495882
FDA-2003-E-0326-0007,FDA,FDA-2003-E-0326,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2005-04-19T04:00:00Z,2005,4,,,2025-10-27T22:54:47Z,,0,0,0900006480495880
FDA-2003-E-0326-0006,FDA,FDA-2003-E-0326,Determination of Regulatory Review Period for Purposes of Patent Extension; Neotame,Notice,Determinations,2004-07-09T04:00:00Z,2004,7,2004-07-06T04:00:00Z,,2025-10-27T22:46:28Z,04-15275,0,0,090000648049587f
FDA-2003-E-0326-0005,FDA,FDA-2003-E-0326,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-06-28T04:00:00Z,2004,6,,,2025-10-27T22:36:52Z,,0,0,090000648049587e
FDA-2003-E-0326-0004,FDA,FDA-2003-E-0326,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2004-01-15T05:00:00Z,2004,1,,,2025-10-27T22:31:58Z,,0,0,090000648049587d
FDA-2003-E-0326-0003,FDA,FDA-2003-E-0326,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-24T05:00:00Z,2003,11,,,2025-10-27T22:28:06Z,,0,0,090000648049587c
FDA-2003-E-0326-0001,FDA,FDA-2003-E-0326,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-06-09T04:00:00Z,2003,6,,,2025-10-27T22:19:06Z,,0,0,090000648049585d
FDA-2003-E-0326-0002,FDA,FDA-2003-E-0326,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-06-09T04:00:00Z,2003,6,,,2025-10-27T22:24:06Z,,0,0,090000648049587b